Image

Health Canada has approved Sunovion Pharmaceuticals Canada’s Aptiom, a voltage-gated sodium channel inhibitor, for use as a once-daily adjunctive therapy for treatment of partial-onset seizures in patients with epilepsy who are not satisfactorily controlled with conventional therapy.

Aptiom’s approval in Canada is supported by data from three Phase III safety and efficacy trials, including BIA-2093-301, BIA-2093-302 and BIA-2093-304.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The three randomised, double-blind, placebo-controlled Phase III clinical trials included more than 1,400 patients with partial-onset seizures inadequately controlled by one to three concomitant antiepileptic drugs, including carbamazepine, lamotrigine, valproic acid and levetiracetam.

"Adequate seizure control remains an unmet medical need for a significant number of patients and Sunovion is committed to providing a treatment option to address this need."

These studies showed that treatment with Aptiom demonstrated statistically significant reductions in standardised seizure frequency versus placebo, and significantly more Aptiom treated patients experienced seizure frequency reduction of 50% or more from baseline.

Dizziness, somnolence, headache, nausea, diplopia, vomiting, fatigue, ataxia, vision blurred, and vertigo are the most frequently reported adverse reactions in patients taking Aptiom.

Sunovion Pharmaceuticals Canada president Douglas Reynolds said: "Adequate seizure control remains an unmet medical need for a significant number of patients and Sunovion is committed to providing a treatment option to address this need."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Portuguese-based BIAL had performed initial research and development of eslicarbazepine acetate and Sunovion acquired the rights under an exclusive license to further develop and commercialise eslicarbazepine acetate in the US and Canadian markets from BIAL.

The US Food and Drug Administration had approved eslicarbazepine acetate in November 2013 as adjunctive treatment of partial-onset seizures.

Image: Aptiom is a once-daily antiepileptic drug indicated for use as adjunctive treatment of partial-onset seizures. Photo: courtesy of Business Wire/ Sunovion Pharmaceuticals Canada Inc.